DiscoverThe JADPRO PodcastA Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

Update: 2023-06-20
Share

Description

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, of Atrium Health, Levine Cancer Institute, in Concord, North Carolina, talks with host Wendy Vogel, MSN, FNP, AOCNP®, on recent data and strategies for managing adverse events of ibrutinib, acalabrutinib, and zanubrutinib in the treatment of B-cell malignancies.

Related Content:

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies. J Adv Pract Oncol 2021;12(4):439–447. https://doi.org/10.6004/jadpro.2021.12.4.8

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

JADPRO